Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Timothy Fenske MD

Timothy Fenske MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center


Publications

  • Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. (Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M) J Hematol Oncol 2017 Jun 12;10(1):117 PMID: 28606176 PMCID: PMC5469142 06/14/2017
  • Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. (Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD) J Clin Oncol 2017 Jul 10;35(20):2260-2267 PMID: 28475457 05/06/2017
  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 PMID: 28468799 PMCID: PMC5510790 05/05/2017
  • Incidence and survival trends in mantle cell lymphoma. (Epperla N, Hamadani M, Fenske TS, Costa LJ) Br J Haematol 2017 Apr 25 PMID: 28444739 04/27/2017
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 04/17/2017
  • Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 03/13/2017
  • Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856 PMID: 28161608 PMCID: PMC5410937 02/06/2017
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Jan 08 PMID: 28066928 01/10/2017
  • RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. (Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW) Br J Haematol 2017 Mar;176(5):759-769 PMID: 27992063 PMCID: PMC5318240 12/20/2016
  • Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. (Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M) Am J Hematol 2017 Feb;92(2):161-170 PMID: 27880984 PMCID: PMC5549936 11/24/2016
  • Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. (Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2016 Dec;16(12):672-678 PMID: 27660080 09/24/2016
  • Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 09/07/2016
  • Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 PMID: 27345140 06/28/2016
  • Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 Sep 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 06/09/2016
  • Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. (Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C) Biol Blood Marrow Transplant 2016 Sep;22(9):1543-1551 PMID: 27131863 PMCID: PMC4981559 05/02/2016
  • Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. (Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2016 Aug;22(8):1440-1448 PMID: 27118571 PMCID: PMC4949103 04/28/2016
  • Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M) Br J Haematol 2016 Jul;174(2):235-48 PMID: 26989808 PMCID: PMC4940282 03/19/2016
  • DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. (Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ) Case Rep Med 2016;2016:8503275 PMID: 26941799 PMCID: PMC4749780 03/05/2016
  • De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. (Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA) Am J Hematol 2016 Jun;91(4):395-9 PMID: 26800311 PMCID: PMC4877689 01/23/2016
  • Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. (Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M) Blood 2016 Feb 18;127(7):938-47 PMID: 26670632 PMCID: PMC4760094 12/17/2015
  • Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. (Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C) Cancer 2016 Feb 15;122(4):559-64 PMID: 26565895 PMCID: PMC5068487 11/14/2015
  • Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. (Epperla N, Fenske TS, Hari PN, Hamadani M) World J Transplant 2015 Sep 24;5(3):81-8 PMID: 26421260 PMCID: PMC4580930 10/01/2015
  • Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. (Chandran R, Gardiner SK, Fenske TS, Spurgeon ES) Leuk Lymphoma 2016;57(4):942-4 PMID: 26292711 08/22/2015
  • Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? (Epperla N, Fenske TS, Lazarus HM, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1393-404 PMID: 26281033 08/19/2015
  • A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. (Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1416-23 PMID: 26237164 PMCID: PMC4633349 08/04/2015
  • A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. (Fenske TS, Shah NM, Kim KM, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS) Cancer 2015 Oct 01;121(19):3465-71 PMID: 26079295 06/17/2015
  • Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. (Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA) Am J Hematol 2015 Sep;90(9):778-83 PMID: 26044261 06/06/2015
  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 04/29/2015
  • Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. (Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS) Bone Marrow Transplant 2015 Jul;50(7):947-53 PMID: 25867651 PMCID: PMC4490016 04/14/2015
  • Post-transplant lymphoproliferative disorders. (Singavi AK, Harrington AM, Fenske TS) Cancer Treat Res 2015;165:305-27 PMID: 25655616 02/07/2015
  • Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 01/27/2015
  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. (Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS) Blood 2014 Oct 09;124(15):2354-61 PMID: 25161267 08/28/2014
  • Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK) Biol Blood Marrow Transplant 2014 Nov;20(11):1729-36 PMID: 25008330 PMCID: PMC4194275 07/11/2014
  • Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. (Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN) Blood 2014 May 01;123(18):2895-7 PMID: 24786458 PMCID: PMC4007615 05/03/2014
  • Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. (Pingali SR, Jewell SW, Havlat L, Bast MA, Thompson JR, Eastwood DC, Bartlett NL, Armitage JO, Wagner-Johnston ND, Vose JM, Fenske TS) Cancer 2014 Jul 15;120(14):2122-9 PMID: 24711253 04/09/2014
  • Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. (Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W) Biol Blood Marrow Transplant 2014 Jul;20(7):951-9 PMID: 24641828 PMCID: PMC4060436 03/20/2014
  • Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. (Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, Fenske TS) Ther Adv Hematol 2014 Feb;5(1):3-12 PMID: 24490019 PMCID: PMC3891289 02/04/2014
  • Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81 PMID: 24344210 PMCID: PMC3897255 12/18/2013
  • Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. (Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN) J Clin Oncol 2013 Sep 01;31(25):3100-9 PMID: 23897963 PMCID: PMC3753702 07/31/2013
  • Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. (Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN) Br J Haematol 2013 Sep;162(5):648-56 PMID: 23829536 PMCID: PMC3766698 07/09/2013
  • Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. (Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR) Biol Blood Marrow Transplant 2013 Sep;19(9):1368-73 PMID: 23806770 06/29/2013
  • Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? (Klyuchnikov E, Bacher U, Kroll T, Shea TC, Lazarus HM, Bredeson C, Fenske TS) Bone Marrow Transplant 2014 Jan;49(1):1-7 PMID: 23708703 05/28/2013
  • Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. (Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M) J Clin Oncol 2013 May 01;31(13):1662-8 PMID: 23478060 PMCID: PMC3635682 03/13/2013
  • Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53 PMID: 23380340 PMCID: PMC3650915 02/06/2013
  • Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31 PMID: 23333532 PMCID: PMC3640440 01/22/2013
  • Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9 PMID: 23200705 PMCID: PMC3553321 12/04/2012
  • Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? (Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR) Blood 2012 Nov 15;120(20):4256-62 PMID: 23007405 PMCID: PMC3501720 09/26/2012
  • Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. (Sehn LH, Fenske TS, Laport GG) Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S82-91 PMID: 22226118 01/18/2012
  • A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. (Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL) Blood 2011 Nov 10;118(19):5119-25 PMID: 21937701 PMCID: PMC3217400 09/23/2011
  • CD23 expression in follicular lymphoma: clinicopathologic correlations. (Olteanu H, Fenske TS, Harrington AM, Szabo A, He P, Kroft SH) Am J Clin Pathol 2011 Jan;135(1):46-53 PMID: 21173123 12/22/2010
  • Central nervous system Hodgkin lymphoma: case report and review of the literature. (Torgerson S, Olteanu H, Tinguely M, Fenske TS) J Neurooncol 2011 Apr;102(2):329-34 PMID: 20676729 08/03/2010
  • Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. (Kroll T, Ames MB, Pruett JA, Fenske TS) Leuk Lymphoma 2010 Sep;51(9):1751-3 PMID: 20629520 07/16/2010
  • Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. (Parker SM, Olteanu H, Vantuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS) Int J Hematol 2009 Dec;90(5):616-22 PMID: 19937165 11/26/2009
  • Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. (Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM) Biol Blood Marrow Transplant 2009 Nov;15(11):1455-64 PMID: 19822306 PMCID: PMC2913553 10/14/2009
  • Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization. (Fenske TS, Benjamin H, Kroft SH, Hohenwalter EJ, Rilling WS) Nat Clin Pract Oncol 2008 Nov;5(11):677-81 PMID: 18797436 09/18/2008
  • Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. (Field JJ, Fenske TS, Blinder MA) Haemophilia 2007 Jan;13(1):46-50 PMID: 17212724 01/11/2007
  • Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? (Hake CR, Graubert TA, Fenske TS) Bone Marrow Transplant 2007 Jan;39(2):59-70 PMID: 17143301 12/05/2006
  • Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. (Fenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA) Cancer Res 2006 May 15;66(10):5029-38 PMID: 16707424 05/19/2006
  • Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. (Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL) Leuk Lymphoma 2005 Oct;46(10):1441-8 PMID: 16194889 10/01/2005
  • Dominant negative effects of the AML1/ETO fusion oncoprotein. (Fenske TS, Pengue G, Graubert TA) Cell Cycle 2005 Jan;4(1):33-6 PMID: 15611635 12/22/2004
  • Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. (Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA) Proc Natl Acad Sci U S A 2004 Oct 19;101(42):15184-9 PMID: 15477599 PMCID: PMC524043 10/13/2004
  • A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1beta2. (Monson NL, Fenske TJ, Wei S, Okragly AJ, de Jong JL, Haak-Frendscho M, O'Shea J, Djeu J, Sondel PM) J Leukoc Biol 2001 Mar;69(3):419-25 PMID: 11261789 03/23/2001
  • Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15. (Farner NL, Gan J, de Jong JL, Leary TP, Fenske TS, Buckley P, Dunlap S, Sondel PM) Cytokine 1997 May;9(5):316-27 PMID: 9195130 05/01/1997
  • Two novel HLA-DQB1*06 alleles reveal additional heterogeneity of HLA-DQw1. (Fenske TS, Baxter-Lowe LA) Tissue Antigens 1992 Jul;40(1):49-52 PMID: 1440562 07/01/1992
  • Characterization of a novel DQB1 allele associated with HLA-DQw3: implications for oligotyping. (Fenske TS, Baxter-Lowe LA) Hum Immunol 1992 Mar;33(3):224-7 PMID: 1618660 03/01/1992
  • Last update: 07/31/2017
    jenkins-FCD Prod-130 96200611f8481f0aa4f84230b11dd74d063847a3